Amjin osteoporosis drug Proe (R) has been approved in China.

Read: Innovative treatment options will benefit postmenopausal women at high risk of fractures!, June 19, 2020 /PRNewswire/ -- Amjin China announces that The pro-® (Prolia ®; generic name: dishua zuma, denosumab) has been approved by the State Drug Administration for the treatment of osteoporosis in postmenopausal women at high risk of fracturesThe approval of The Prolife® became the first in China and is currently the only anti-RANKL monoantiapitic drug used in the treatment of osteoporosis, which can help postmenopausal women significantly reduce the risk of vertebral, non-vertebral and hip fractures, and bring innovative opportunities for bone health management and quality of life improvement in Chinese patientsosteoporosis is a disease caused by excessive bone lossThe number of people over the age of 50 in China with osteoporosis has almost doubled in the past decadeCurrently, one in three Chinese women over the age of 50 is sickOsteoporosis is known as the "silent killer" and the link between it and fractures has not been widely recognized by the publicIn fact, many women often realize that they have osteoporosis after developing osteoporosis fractures in the wrist, vertebrae, hips, etc., and are five times more likely to break again within a year"osteoporosis fractures can last for life and are one of the leading causes of disability and death in older patients, such as 20 per cent of patients who die from complications within one year of hip fracturesProfessor Zhang Zhenlin, Chairman of the Osteoporosis and Osteoporosis Branch of the Chinese Medical Association and Director of Osteoporosis and Osteopathy department of the Sixth People's Hospital affiliated with Shanghai Jiaotong University, said, "Responding to osteoporosis requires scientific disease management, and daily regular exercise and nutritional intake are far from enough." We call on patients to undergo standardized medications to help reduce bone loss, increase bone density, and reduce the incidence of fractures"As the aging population ages, osteoporosis is placing an increasing burden of disease on Chinese society," said DrDavid MReese, executive vice president of research and development atAmgentThe approval of the Prolife® is a landmark for millions of women with osteoporosis in ChinaAt the same time, it is also an important step forwardIn the future, we will continue to actively introduce innovative treatment options for more Chinese patients studies have shown that proly ® can increase bone density in postmenopausal osteoporosis patients over a 10-year period: in a critical Phase III clinical trial of 7,808 postmenopausal osteoporosis patients, Prolifer® demonstrated superior long-term efficacy and safety The subjects continued to use pro-® over a three-year trial period and over a later seven-year period, and the bone density of the lumbar spine and whole hip increased by an average of 21.7% and 9.2% compared to the baseline, effectively reducing the risk of vertebral, non-vertebral and hip fractures "The unstoppable aging process has brought unprecedented public health challenges to Chinese society," said Ms Ke Meiling, vice president and general manager of an ad minced In China, Amin is committed to exploring effective treatment options in the field of chronic diseases to promote healthy aging and to help build a 'healthy China 2030' We will spare no effort to accelerate the launch of the Proli ® and work closely with the Chinese government to meet the medical needs of patients with osteoporosis in China References: Chen et al BMC Public Health (2016) 16:1039 The National Health and Health Administration has released the results of the epidemiological survey of osteoporosis in China AccessEd October 8, 2019 van Geel TA, et al Clinical heath ath a tha a' cluster in time after first fractures Ann Rheum Dis 2009; 68:99-102 Kanis JA, Johnell O, De Laet C, et al (2004) a meta-fractures of the fractures and hea Bone 35:375 Chinese Medical Association Osteoporosis and Osteoporosis And Osteoporosis Guidelines for Primary Osteoporosis (2017) Chinese Journal of Osteoporosis and Osteoporosis, 2017, 10 (5): 413-443 doi: 10.3969/j.issn.1674-2591.2017.05.002 , Bone, HG RBman, Brandi ML, et al 10 years of denosumab in post-postdessdes Lancet Diabetes Endocrinol 2017 ;5(7) : 513-523 AccessEd April 20, 2020 ®() ®(:Prolia®;:,denosumab)RANKL。 At present, the Company ® has been approved for listing in more than 80 countries and regions around the world Proli ® approved for osteoporosis in postmenopausal women at high risk of fractures Proli ® should be administered every 6 months at a dose of 60 mg .